Showing 7171-7180 of 20410 results for "".
Studying the Safety of Discontinuing DMTs in MS Older Adults
https://reachmd.com/programs/neurofrontiers/studying-the-safety-of-discontinuing-dmts-in-ms-older-adults/15816/A recent study investigated whether stopping therapy in older patients with MS allowed disease activity to increase. Discover the data.EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
https://reachmd.com/clinical-practice/oncology-hematology/eha-2026-sonrotoclax-plus-zanubrutinib-in-frontline-cll/59180/Explore updated MRD findings with sonrotoclax plus zanubrutinib in treatment-naïve patients with CLL/SLL.Finerenone Subgroup Analyses in Patients With Glomerulonephritis
https://reachmd.com/clinical-practice/nephrology/finerenone-subgroup-analyses-in-patients-with-glomerulonephritis/57918/Review subgroup findings for finerenone in patients with glomerulonephritis and CKD, as presented at ERA 2026.The Ambulatory HFrEF Blind Spot: Proactively Reducing CV Mortality Risk Despite Optimized GDMT
https://reachmd.com/programs/cme/the-ambulatory-hfref-blind-spot-proactively-reducing-cv-mortality-risk-despite-optimized-gdmt/48810/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.EHA 2026: Long-Term Zanubrutinib Outcomes
https://reachmd.com/clinical-practice/oncology-hematology/eha-2026-long-term-zanubrutinib-outcomes/59181/Review long-term safety and efficacy data from the SEQUOIA trial evaluating zanubrutinib in treatment-naïve patients aged ≥80 years with CLL/SLL.Precision in Practice—Bringing Targeted Therapy to mHSPC
https://reachmd.com/programs/cme/precision-in-practicebringing-targeted-therapy-to-mhspc/57201/Explore individualized treatment intensification, molecular profiling, and adverse event management in metastatic hormone-sensitive prostate cancer.Beyond the Sum of Their Parts: Overcoming Disparities in Care
https://reachmd.com/programs/project-oncology/beyond-the-sum-of-their-parts-overcoming-disparities-in-care/13668/Find out more about the steps we can take to promote intersectionality and provide better patient care.Amyloid-β Therapies in Practice: Not All Are Created Equal
https://reachmd.com/programs/cme/Amyloid-Therapies-in-Practice-Not-All-Are-Created-Equal/56761/Examine integrated neurodegenerative and neuropsychiatric features of Alzheimer’s disease, including NPS biology and therapeutic strategies.NPS Agitation: Evidence and Emerging Mechanisms of Management
https://reachmd.com/programs/cme/nps-agitation-evidence-and-emerging-mechanisms-of-management/56766/Examine integrated neurodegenerative and neuropsychiatric features of Alzheimer’s disease, including NPS biology and therapeutic strategies.Optimizing Care of the Hospitalized Patient With Overt Hepatic Encephalopathy
https://reachmd.com/programs/cme/Optimizing-Care-of-the-Hospitalized-Patient-With-Overt-Hepatic-Encephalopathy/39792/Explore diagnostic and treatment challenges in patients with hepatic encephalopathy to improve outcomes for your patients.